A novel read methodology to evaluate the optimal dose of (68)Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

BACKGROUND: (68)Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to (68)Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal peptide mass and radioactivity ranges for (68)...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Colin G., Grønbæk, Henning, Virgolini, Irene, Kjaer, Andreas, Terve, Pierre, Bahri, Shadfar, Iversen, Peter, Svirydenka, Hanna, Rohban, Thomas, McEwan, Sandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421477/
https://www.ncbi.nlm.nih.gov/pubmed/34487283
http://dx.doi.org/10.1186/s13550-021-00819-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421477/
https://www.ncbi.nlm.nih.gov/pubmed/34487283
http://dx.doi.org/10.1186/s13550-021-00819-1

Ejemplares similares